<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1110211126
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Cincet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CINACALCET
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        221.20
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Aurobindo Pharma Limited Unit XV" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Aurobindo Pharma Limited Unit XV
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 3103]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Aurobindo Pharma Saudi Arabia Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Aurobindo Pharma Saudi Arabia Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        H05BX01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Cincet works by controlling the levels of parathyroid hormone (PTH), calcium and phosphorous in your body. It is used to treat problems with organs called parathyroid glands. The parathyroids are four small glands in the neck, near the thyroid gland, that produce parathyroid hormone (PTH).</p><p><strong>Cincet is used in adults:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp; to treat secondary hyperparathyroidism in adults with serious kidney disease who need dialysis to clear their blood of waste products.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; to reduce high levels of calcium in the blood (hypercalcaemia) in adult patients with parathyroid cancer.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; to reduce high levels of calcium in the blood (hypercalcaemia) in adult patients with primary hyperparathyroidism when removal of the gland is not possible.</p><p><strong>Cincet is used in children aged 3 years to less than 18 years of age:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp; to treat secondary hyperparathyroidism in patients with serious kidney disease who need dialysis to clear their blood of waste products, whose condition is not controlled with other treatments.</p><p><strong>&nbsp;</strong></p><p>In primary and secondary hyperparathyroidism too much PTH is produced by the parathyroid glands. &ldquo;Primary&rdquo; means that the hyperparathyroidism is not caused by any other condition and &ldquo;secondary&rdquo; means that the hyperparathyroidism is caused by another condition, e.g. kidney disease. Both primary and secondary hyperparathyroidism can cause the loss of calcium in the bones, which can lead to bone pain and fractures, problems with blood and heart vessels, kidney stones, mental illness and coma.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take </strong><strong>Cincet</strong> if you are allergic to cinacalcet or any of the other ingredients of this medicine (listed in section 6).</p><p><strong>Do not take </strong><strong>Cincet</strong> if you have low levels of calcium in your blood. Your doctor will monitor your blood calcium levels.</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor, pharmacist or nurse before taking Cincet.</p><p>Before you start taking Cincet, tell your doctor if you have or have ever had:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>seizures</strong> (fits or convulsions). The risk of having seizures is higher if you have had them before;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>liver problems;</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>heart failure.</strong></p><p>Cincet reduces calcium levels. Life threatening events and fatal outcomes associated with low calcium levels (hypocalcaemia) have been reported in adults and children treated with Cincet.</p><p>Please tell your doctor if you experience any of the following which may be signs of low calcium levels: spasms, twitches, or cramps in your muscles, or numbness or tingling in your fingers, toes or around your mouth or seizures, confusion or loss of consciousness while being treated with Cincet.</p><p>Low calcium levels can have an effect on your heart rhythm. Tell your doctor if you experience an unusually fast or pounding heartbeat, if you have heart rhythm problems, or if you take medicines known to cause heart rhythm problems, while taking Cincet.</p><p>For additional information see section 4.</p><p>During treatment with Cincet, tell your doctor:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you start or stop smoking, as this may affect the way Cincet works.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Children under the age of 18 with parathyroid cancer or primary hyperparathyroidism must not take Cincet.</p><p>If you are being treated for secondary hyperparathyroidism, your doctor should monitor your calcium levels before starting treatment with Cincet and during treatment with Cincet. You should inform your doctor if you experience any of the signs of low calcium levels as described above.</p><p>It is important that you take your dose of Cincet as advised by your doctor.</p><p><strong>Other medicines and </strong><strong>Cincet</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines particularly etelcalcetide or any other medicines that lower the level of calcium in your blood.</p><p>You should not receive Cincet together with etelcalcetide.</p><p>Tell your doctor if you are taking the following medicines</p><p>Medicines such as these can affect how Cincet works:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat <strong>skin </strong>and <strong>fungal infections </strong>(ketoconazole, itraconazole and voriconazole);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat <strong>bacterial infections </strong>(telithromycin, rifampicin and ciprofloxacin);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a medicine used to treat <strong>HIV </strong>infection and AIDS (ritonavir);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a medicine used to treat <strong>depression </strong>(fluvoxamine).</p><p>Cincet may affect how medicines such as the following work:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat <strong>depression </strong>(amitriptyline, desipramine, nortriptyline and clomipramine);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a medicine used to relieve <strong>cough </strong>(dextromethorphan);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat <strong>changes in heart rate </strong>(flecainide and propafenone);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a medicine used to treat <strong>high blood pressure </strong>(metoprolol).</p><p><strong>Cincet</strong> <strong>with food and drink</strong></p><p>Cincet should be taken with or shortly after food.</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>Cincet has not been tested in pregnant women. In case of pregnancy, your doctor may decide to modify your treatment, as Cincet might harm the unborn baby.</p><p>It is not known whether Cincet is excreted in human milk. Your doctor will discuss with you if you should discontinue either breast-feeding or treatment with Cincet.</p><p><strong>Driving and using machines</strong></p><p>Dizziness and seizures have been reported by patients taking Cincet. If you experience these side effects, do not drive or operate machines.</p><p><strong>Cincet</strong> <strong>contains lactose</strong></p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are unsure. Your doctor will tell you how much Cincet you must take.</p><p>Cincet must be taken orally, with or shortly after food. The tablets must be taken whole and are not to be chewed, crushed or divided.</p><p>Cincet is also available as granules in capsules for opening. Children who require doses lower than 30 mg, or who are unable to swallow tablets should receive Cincet granules.</p><p>Your doctor will take regular blood samples during treatment to monitor your progress and will adjust your dose if necessary.</p><p><strong><em>If you are being treated for secondary hyperparathyroidism</em></strong></p><p>The usual starting dose for Cincet in adults is 30 mg (one tablet) once per day.</p><p>The usual starting dose of Cincet for children aged 3 years to less than 18 years of age is no more than 0.20 mg/kg of body weight daily.</p><p><strong><em>If you are being treated for parathyroid cancer or primary hyperparathyroidism</em></strong></p><p>The usual starting dose for Cincet in adults is 30 mg (one tablet) twice per day.</p><p><strong>If you take more </strong><strong>Cincet</strong> <strong>than you should</strong></p><p>If you take more Cincet than you should you must contact your doctor immediately. Possible signs of overdose include numbness or tingling around the mouth, muscle aches or cramps and seizures.</p><p><strong>If you forget to take </strong><strong>Cincet</strong></p><p>Do not take a double dose to make up for a forgotten dose.</p><p>If you have forgotten a dose of Cincet, you should take your next dose as normal.</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Please tell your doctor immediately:</strong></p><p>If you start to get numbness or tingling around the mouth, muscle aches or cramps and seizures. These may be signs that your calcium levels are too low (hypocalcaemia).</p><p>If you experience swelling of the face, lips, mouth, tongue or throat which may cause difficulty in swallowing or breathing (angioedema).</p><p><strong>&nbsp;</strong></p><p><strong>Very common: may affect more than 1 in 10 people</strong></p><p>nausea and vomiting, these side effects are normally quite mild and do not last for long.</p><p><strong>Common: may affect up to 1 in 10 people</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; numbness or tingling sensation (paraesthesia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss (anorexia) or decrease of appetite</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle pain (myalgia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weakness (asthenia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced testosterone levels</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high potassium levels in the blood (hyperkalaemia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions (hypersensitivity)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; seizures (convulsions or fits)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure (hypotension)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; upper respiratory infection</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breathing difficulties (dyspnoea)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; indigestion (dyspepsia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal pain, abdominal pain &ndash; upper</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle spasms</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; back pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low calcium levels in the blood (hypocalcaemia).</p><p><strong>Not known: frequency cannot be estimated from available data</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hives (urticaria)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of the face, lips, mouth, tongue or throat which may cause difficulty in swallowing or breathing (angioedema)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unusually fast or pounding heart beat which may be associated with low levels of calcium in your blood (QT prolongation and ventricular arrhythmia secondary to hypocalcaemia).</p><p>After taking Cincet a very small number of patients with heart failure had worsening of their condition and/or low blood pressure (hypotension).</p><p><strong>Reporting of side effects </strong></p><p>If you get any side effects talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month.</p><p>Store below 30&deg;C</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away any medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is Cinacalcet Hydrochloride.</p><p>Each film-coated tablet contains Cinacalcet Hydrochloride equivalent to Cinacalcet 30/60 mg.</p><p>The other ingredients are:</p><p><em>Tablet core</em>: Starch, pregelatinised, Crospovidone, Cellulose, Microcrystalline, Silica colloidal anhydrous, Sodium stearyl fumarate.</p><p><em>Tablet coating:</em></p><p>Opadry II Green 32K510004 (contains Lactose monohydrate, Hypromellose, Titanium Dioxide, Triacetin, Iron oxide yellow, FD&amp;C blue #2/indigo caramine aluminium lake)</p><p>Aquarius BP 19156 ICE (Hypromellose, Polyethylene glycol)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Cincet 30: 
Light green, oval shaped, biconvex, film-coated tablets debossed with “CN” on one side and “30” on the other side.
Cincet 60:  
Light green, oval shaped, biconvex, film-coated tablets debossed with “C” and “N” on either side of break line on one side and “60” on the other side.

Cincet 30 mg & 60 mg tablets are supplied in 28’s pack (7’s Blister x 4).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufacturer </strong></p><p>Aurobindo Pharma Limited, Unit-XV,</p><p>Plot No. 17 A, E. Bonangi (V),</p><p>Jawaharlal Nehru Pharma City,</p><p>Parawada (M), Visakhapatnam Dist,</p><p>Andhra Pradesh, India.</p><p><strong>&nbsp;</strong></p><p><strong>Marketing Authorisation Holder </strong></p><p>Aurobindo Pharma Saudi Arabia Limited,</p><p>Jeddah, Saudi Arabia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                06/2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">&nbsp;يعمل سينسيت عبر التحكم في مستويات الهرمون الجاردرقي (PTH) والكالسيوم والفوسفور في جسدك. ويستخدم لعلاج مشاكل بأعضاء تُسمى الغدد الجاردرقية. وتتكون الغدد الجاردرقية من أربع غدد صغيرة في العنق، بالقرب من الغدة الدرقية، واللاتي تُنتج الهرمون الجاردرقي (PTH).</p><p dir="RTL"><strong>يُستخدم سينسيت في البالغين:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج فرط الدريقات الثانوي في البالغين المصابين بأمراض كلوية حادة، والذين يحتاجون لغسيل كلوي لتصفية دمائهم من المنتجات المُتخلفة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لخفض مستويات الكالسيوم المرتفعة في الدم (فرط كالسيوم الدم) لدي المرضى البالغين المصابين بالسرطان الجاردرقي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لخفض مستويات الكالسيوم المرتفعة في الدم (فرط كالسيوم الدم) لدي المرضى البالغين المصابين بفرط الدريقات عندما يكون خيار إزالة الغدة غير متاح.</p><p dir="RTL"><strong>يُستخدم سينسيت مع الأطفال من عمر 3 إلى أقل من 18 عام:</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>لعلاج فرط الدريقات الثانوي في المرضى المصابين بأمراض كلوية حادة، والذين يحتاجون لغسيل كلوي لتصفية دمائهم من المنتجات المُتخلفة، والذين لا تفلح العلاجات الأخرى في التحكم في حالتهم.</p><p><strong>&nbsp;</strong></p><p dir="RTL">يُنتج الهرمون الجاردرقي (PTH) بكمية كبيرة بواسطة الغدد الجاردرقية في حالة فرط الدريقات الأساسي والثانوي. &quot;الأساسي&quot; تعني أن فرط الدريقات لم تتسبب فيه أية حالة أخرى، و&quot;الثانوي&quot; تعني أن فرط الدريقات سببته حالة أخرى. على سبيل المثال، مرض كلوي. كلا من فرط الدريقات الأساسي والثانوي يُمكن أن يتسبب في خفض الكالسيوم في العظام، والذي قد يؤدي إلى آلام العظام وكسورها، ومشاكل بالدم وأوعية القلب، وحصوات الكلى، وأمراض عقلية وغيبوبة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تأخذ سينسيت</strong> إذا كانت لديك حساسية تجاه سيناكالسيت أو أي من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6).</p><p dir="RTL"><strong>لا تأخذ سينسيت</strong> إن كانت مستويات الكالسيوم في دمك منخفضة. سيراقب الطبيب مستويات&nbsp;الكالسيوم في دمك.</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">تحدث مع طبيبك أو الصيدلي أو الممرضة قبل أخذ سينسيت.</p><p dir="RTL"><strong>قبل بدء العلاج بسينسيت</strong>، أعلم طبيبك إن كنت مصابًا أو أُصبت قبلًا بـ:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>نوبات</strong> (تشنجات أو ارتعاشات). تزداد خطورة الإصابة بالنوبات إن كنت مصابًا بهم من قبل.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>مشاكل كبدية.</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>فشل بالقلب.</strong></p><p dir="RTL">يُخفض سينسيت من مستويات الكالسيوم. أٌبلغ عن حدوث حالات مُهددة للحياة ونتائج مميتة ارتبطت بمستويات الكالسيوم المنخفضة (قلة كالسيوم الدم) لدي البالغين والأطفال الذين عولجوا بسينسيت.</p><p dir="RTL">من فضلك أعلم الطبيب أن أُصبت بأي من التالي، والذي قد يكون علامات لانخفاض مستويات الكالسيوم: تشنجات أو اختلاجات أو تقلصات بالعضلات، أو تنميل أو وخز في أصابع اليدين أو القدمين أو حول الفم، أو نوبات أو ارتباك أو فقدان للوعي أثناء العلاج بسينسيت.</p><p dir="RTL">قد يؤثر انخفاض مستويات الكالسيوم على نظم القلب. أعلم الطبيب إن عانيت من نبضات قلب سريعة أو طارقة بشكل غير معتاد، أو إن كنت تعاني من مشاكل بنظم القلب، أو إن كنت تأخذ أدوية معلوم تسببها في مشاكل بنظم القلب بالتزامن مع أخذ سينسيت.</p><p dir="RTL">للمزيد من المعلومات، انظر القسم.</p><p dir="RTL">أثناء العلاج بسينسيت، أعلم الطبيب:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن بدأت أو توقفت عن التدخين، فقد يؤثر ذلك على طريقة عمل سينسيت.</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">يجب على الأطفال الأقل من 18 عام والمصابين بالسرطان الجاردرقي أو فرط الدريقات الأساسي ألا يأخذوا سينسيت.</p><p dir="RTL">إن كنت تُعالج من فرط الدريقات الثانوي، يجب أن يراقب الطبيب مستويات الكالسيوم لديك قبل بدء العلاج بسينسيت وأثناء العلاج بسينسيت. يجب أن تُعلم طبيبك إن عانيت من أي من علامات انخفاض مستويات الكالسيوم كما هو مذكور أعلاه.</p><p dir="RTL">من المهم أن تأخذ جرعتك من سينسيت كما أخبرك طبيبك.</p><p dir="RTL"><strong>الأدوية الأخرى وسينسيت</strong></p><p dir="RTL">أعلم طبيبك أو الصيدلي إن كنت تأخذ أو أخذت حديثًا أو قد تأخذ أية أدوية أخرى، وخاصة إيتيلكالسيتيد أو أي أدوية أخرى من شأنها خفض مستوى الكالسيوم في دمك.</p><p dir="RTL">يجب ألا تأخذ سينسيت بالتزامن مع إيتيلكالسيتيد.</p><p dir="RTL">أعلم طبيبك إذا كنت تأخذ أي من الأدوية التالية</p><p dir="RTL">يُمكن للأدوية المماثلة للتالي التأثير على آلية عمل سينسيت:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج <strong>الجلد</strong> و<strong>العدوات الفطرية</strong> (كيتوكونازول، إيتراكونازول، فوريكونازول).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج <strong>العدوات البكتيرية</strong> (تيليثرومايسين، ريفامبيسين، سيبروفلوكساسين).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دواء يُستخدم لعلاج عدوات فيروس نقص المناعة البشرية (<strong>HIV</strong>) والأيدز (ريتونافير).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دواء يُستخدم لعلاج <strong>الاكتئاب</strong> (فلوفوكسامين).</p><p dir="RTL">قد يؤثر سينسيت على آلية عمل الأدوية المماثلة للتالي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المُستخدمة لعلاج <strong>الاكتئاب</strong> (أميتريبتايلين، ديسيبرامين، نوتريبتايلين، كلوميبرامين).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دواء يُستخدم لعلاج <strong>السعال</strong> (ديكستروميثورفان).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج <strong>تغيرات معدل القلب</strong> (فليكينيد وبروبافينون).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دواء يُستخدم لعلاج <strong>ارتفاع ضغط الدم</strong> (ميتوبرولول).</p><p dir="RTL"><strong>سينسيت مع الطعام والشراب</strong></p><p dir="RTL">يجب أخذ سينسيت مع الطعام أو بعده بفترة قليلة.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية والخصوبة</strong></p><p dir="RTL">إذا كنتِ حاملًا أو تقومين بالإرضاع، أو يُحتمل أن تصبحين حاملًا أو تخططين لإنجاب طفل، يجب عليكِ أخذ مشورة طبيبك أو الصيدلي قبل استعمال هذا الدواء.</p><p dir="RTL">لم يُختبر سينسيت لدي النساء الحوامل. في حالة الحمل، قد يقرر الطبيب تعديل علاجك، فقد يضر سينسيت بجنينك.</p><p dir="RTL">من غير المعلوم ما إذا كان سينسيت يُفرز في الحليب البشري أم لا. سيناقش الطبيب معكِ إن كان ضروريًا إيقاف الإرضاع الطبيعي أو العلاج بسينسيت.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">سُجلت حالات من الدوخة والنوبات لدي المرضى الذين يتناولون سينسيت. إذا عانيت من هذه الآثار الجانبية، لا تقم بالقيادة أو تشغيل الآلات.</p><p dir="RTL"><strong>يحتوي سينسيت على اللاكتوز</strong></p><p dir="RTL">إذا أخبرك طبيبك بعدم قدرتك على تحمل بعض السكريات، فعليك الاتصال بطبيبك قبل أخذ هذا المنتج الطبي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">خذ هذا الدواء دائمًا كما أخبرك طبيبك أو الصيدلي بالضبط، وتحقق من طبيبك أو الصيدلي إن لم تكن متأكدًا. سيخبرك طبيبك بالجرعة الواجب أخذها من سينسيت.</p><p dir="RTL">يجب أخذ سينسيت فمويًا مع الطعام أو بعده بفترة قليلة. كما يجب أخذ الأقراص كاملة، ويجب عدم مضغها أو طحنها أو تقسيمها.</p><p dir="RTL">سينسيت متوفر أيضًا في صورة حبيبات في كبسولات قابلة للفتح. يجب على الأطفال الذين يحتاجون لجرعات أقل من 30 مجم، أو غير القادرين على ابتلاع الأقراص، أن يتلقوا حبيبات سينسيت.</p><p dir="RTL">سيأخذ الطبيب عينات دم دورية أثناء العلاج لمتابعة تقدمك، وسيعدل جرعتك عند الحاجة.</p><p dir="RTL"><strong><em>إن كنت تُعالج من فرط الدريقات الثانوي</em></strong></p><p dir="RTL">جرعة البدء المعتادة من سينسيت لدي البالغين هي 30 مجم (قرص واحد) مرة واحدة يوميًا.</p><p dir="RTL">جرعة البدء المعتادة من سينسيت للأطفال من سن 3 سنوات لأقل من 18 عام لا تزيد عن 0.20 مجم/كجم من وزن الجسم يوميًا.</p><p dir="RTL"><strong><em>إن كنت تُعالج من السرطان الجاردرقي أو فرط الدريقات الأساسي</em></strong></p><p dir="RTL">جرعة البدء المعتادة من سينسيت لدي البالغين هي 30 مجم (قرص واحد) مرتين يوميًا.</p><p dir="RTL"><strong>إذا أخذت أكثر مما يجب من سينسيت</strong></p><p dir="RTL">تحدث مع طبيبك على الفور إذا أخذت أكثر مما يجب من سينسيت. العلامات المُمكنة للجرعة المفرطة تتضمن التنميل أو الوخز حول الفم وآلام العضلات أو تشنجها والنوبات.</p><p dir="RTL"><strong>إذا نسيت تناول سينسيت</strong></p><p dir="RTL">لا تأخذ جرعة مزدوجة للتعويض عن الجرعة المنسية.</p><p dir="RTL">إن نسيت جرعة من سينسيت، يجب أن تأخذ جرعتك التالية وفقًا للمعتاد.</p><p dir="RTL">إذا كان لديك المزيد من الأسئلة حول استخدام هذا الدواء، اسأل طبيبك أو الممرضة أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;مثل جميع الأدوية، قد يتسبب هذا الدواء بآثار جانبية، بالرغم من عدم إصابة الجميع بها.</p><p dir="RTL"><strong>من فضلك أعلم طبيبك على الفور:</strong></p><p dir="RTL">إن ظهر عليك تنميل أو وخز حول الفم وآلام أو تشنج بالعضلات ونوبات. قد تكون تلك علامات لشدة انخفاض مستويات الكالسيوم (قلة الكالسيوم في الدم).</p><p dir="RTL">إذا عانيت من تورم بالوجه أو الشفتين أو الفم أو اللسان أو الحلق، قد يؤدي إلى صعوبة بالتنفس (وذمة وعائية).</p><p dir="RTL"><strong>شائعة جدًا: قد تؤثر على أكثر من 1 لكل 10 أشخاص</strong></p><p dir="RTL">غثيان وقيء، عادة ما تكون تلك الآثار الجانبية بسيطة جدًا ولا تستمر طويلًا.</p><p dir="RTL"><strong>شائعة: قد تؤثر على 1 لكل 10 أشخاص</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تنميل أو شعور بالوخز (مذل)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية أو انخفاضها</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام العضلات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف (فقدان القوة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات التستوستيرون</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستويات البوتاسيوم في الدم (فرط البوتاسيوم في الدم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات تحسسية (فرط الحساسية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات (ارتعاشات أو تشنجات)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجهاز التنفسي العلوي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة التنفس (بحة الصوت)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عسر هضم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالبطن، ألم بأعلى البطن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمساك</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>تشنجات عضلية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالظهر</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>انخفاض مستويات الكالسيوم في الدم (قلة الكالسيوم في الدم).</p><p dir="RTL"><strong>غير معلومة: لا يمكن تحديد التكرارية من البيانات المتاحة</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شرى (أرتيكاريا).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم بالوجه أو الشفتين أو الفم أو اللسان أو الحلق، قد يؤدي إلى صعوبة بالبلع أو التنفس (وذمة وعائية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبضات قلب سريعة أو طارقة بصورة غير معتادة قد تتزامن مع انخفاض مستويات الكالسيوم في الدم (استطالة موجات QT واضطراب النظم البطيني الناجم عن قلة الكالسيوم في الدم).</p><p dir="RTL">تفاقمت حالة عدد قليل جدًا من المرضى المصابين بفشل القلب بعد أخذ سينسيت</p><p dir="RTL">و/أو أصيبوا بانخفاض ضغط الدم.</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">&nbsp;إذا حدث لك أي آثار جانبية، تحدث مع طبيبك أو الصيدلي أو الممرضة. ويتضمن ذلك أي آثار جانبية محتملة غير مدرجة بهذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إحفظ هذا الدواء بعيدا عن نظر الأطفال ومتناول أيديهم.</p><p dir="RTL">&nbsp;لا تستخدم هذا الدواء بعد تاريخ الانتهاء المذكور على الكرتون بعد &ldquo;EXP&rdquo;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.</p><p dir="RTL">&nbsp;يُخزن في درجة حرارة أقل من 30 درجة مئوية</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق الصرف الصحي أو النفايات المنزلية. أسال الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه التدابير تساعد في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;المادة الفعالة هي سيناكالسيت هيدروكلوريد.</p><p dir="RTL">&nbsp;يحتوي كل قرص مُغلف على سيناكالسيت هيدروكلوريد يكافئ سيناكالسيت 30/60 مجم.</p><p dir="RTL">&nbsp;المكونات الأخرى هي:</p><p dir="RTL"><em>&nbsp;جسم القرص:</em> نشا متصلب مسبقًا، كروسبوفيدون، سيليولوز دقيق التبلور، سيليكا غروية لا مائية، ستيريل فيومارات الصوديوم.</p><p dir="RTL"><em>غلاف القرص:</em></p><p dir="RTL">أوبادري II أخضر 32K510004 (يحتوي على لاكتوز أحادي الماء، هيبروميلوز، ثاني أكسيد التيتانيوم، ترياسيتين، أكسيد حديد أصفر، FD&amp;C أزرق #2/صبغة إنديجو كارمين الألمونيومية الترسيبية)</p><p dir="RTL">أكواريوس BP 19156 ICE (هيبروميلوز، بولي إيثيلين جليكول)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><u>&nbsp;سينسيت 30</u></p><p>&nbsp;أقراص بيضاوية مغلفة ثنائية التحدب خضراء فاتحة، محفور على أحد جانبيها &ldquo;CN&quot;، و&rdquo;30&rdquo; على الجانب الآخر.</p><p><u>سينسيت 60&nbsp; </u></p><p>أقراص بيضاوية مغلفة ثنائية التحدب خضراء فاتحة، محفور على أحد جانبيها &quot;C&quot; و&quot;N&quot; على كلا جانبي الخط الفاصل، و&rdquo;60&rdquo; على الجانب الآخر.</p><p dir="RTL">تُورد أقراص سينسيت 30 مجم و60 مجم في عبوة تحتوي على 28 قرص (4 أشرطة يحتوي كل منها على 7 أقراص).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركة المُصنعة:</strong></p><p dir="RTL">&nbsp;أوروبيندو فارما المحدودة، الوحدة - XV</p><p dir="RTL">قطعة رقم 17 A، إ. بونانجي (V)،</p><p dir="RTL">مدينة جواهارلال نيهرو الدوائية ،</p><p dir="RTL">باراوادا (M)، حي فيساكهاباتنام،</p><p dir="RTL">أندهرا براديش، الهند.</p><p dir="RTL"><strong>حامل ترخيص التسويق</strong></p><p dir="RTL">&nbsp;أوروبيندو فارما السعودية المحدودة،</p><p dir="RTL">جدة، المملكة العربية السعودية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            06/2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Cincet 30 (Cinacalcet Tablets 30 mg) 
Cincet 60 (Cinacalcet Tablets 60 mg)
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Cinacalcet Tablets 30 mg:
Each film-coated tablet contains Cinacalcet Hydrochloride equivalent to Cinacalcet 30 mg
Cinacalcet Tablets 60 mg:
Each film-coated tablet contains Cinacalcet Hydrochloride equivalent to Cinacalcet 60 mg

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Cinacalcet Tablets 30 mg:
Light green, film-coated, oval shaped, biconvex tablets debossed with “CN” on one side and “30” on the other side.
Cinacalcet Tablets 60 mg:
Light green, film-coated, oval shaped, biconvex tablets debossed with “C” and “N” on either side of break line on one side and “60” on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Secondary hyperparathyroidism</u></p><p><em>Adults</em></p><p>Treatment of secondary hyperparathyroidism (HPT) in adult patients with end-stage renal disease (ESRD) on maintenance dialysis therapy.</p><p><em>Paediatric population</em></p><p>Treatment of secondary hyperparathyroidism (HPT) in children aged 3 years and older with end-stage renal disease (ESRD) on maintenance dialysis therapy in whom secondary HPT is not adequately controlled with standard of care therapy.</p><p>Cinacalcet Tablets may be used as part of a therapeutic regimen including phosphate binders and/or Vitamin D sterols, as appropriate.</p><p><u>Parathyroid carcinoma and primary hyperparathyroidism in adults</u></p><p>Reduction of hypercalcaemia in adult patients with:</p><p>&bull; parathyroid carcinoma.</p><p>&bull; primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Posology</strong></p><p><em><u>Secondary hyperparathyroidism</u></em></p><p><em>Adults and elderly (&gt; 65 years)</em></p><p>The recommended starting dose for adults is 30 mg once per day. Cinacalcet Tablets should be titrated every 2 to 4 weeks to a maximum dose of 180 mg once daily to achieve a target parathyroid hormone (PTH) in dialysis patients of between 150-300 pg/mL (15.9-31.8 pmol/L) in the intact PTH (iPTH) assay. PTH levels should be assessed at least 12 hours after dosing with Cinacalcet Tablets. Reference should be made to current treatment guidelines.</p><p>PTH should be measured 1 to 4 weeks after initiation or dose adjustment of Cinacalcet Tablets. PTH should be monitored approximately every 1-3 months during maintenance. Either the intact PTH (iPTH) or bio-intact PTH (biPTH) may be used to measure PTH levels; treatment with Cinacalcet Tablets does not alter the relationship between iPTH and biPTH.</p><p><em>Dose adjustment based on serum calcium levels</em></p><p>Corrected serum calcium should be measured and monitored and should be at or above the lower limit of the normal range prior to administration of first dose of Cinacalcet Tablets. The normal calcium range may differ depending on the methods used by your local laboratory.</p><p>During dose titration, serum calcium levels should be monitored frequently, and within 1 week of initiation or dose adjustment of Cinacalcet Tablets. Once the maintenance dose has been established, serum calcium should be measured approximately monthly. In the event that corrected serum calcium levels fall below 8.4 mg/dL (2.1 mmol/L) and/or symptoms of hypocalcaemia occur the following management is recommended:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Corrected Serum calcium level or clinical</strong></p><p><strong>symptoms of hypocalcaemia</strong></p></td><td><p><strong>Recommendations</strong></p></td></tr><tr><td style="vertical-align:top"><p>&lt; 8.4 mg/dL (2.1 mmol/L) and &gt; 7.5 mg/dL (1.9 mmol/L), or in the presence of clinical symptoms of hypocalcaemia</p></td><td style="vertical-align:top"><p>Calcium-containing phosphate binders, vitamin D sterols and/or adjustment of dialysis fluid calcium concentrations can be used to raise serum calcium according to clinical judgment.</p></td></tr><tr><td style="vertical-align:top"><p>&lt; 8.4 mg/dL (2.1 mmol/L) and &gt; 7.5 mg/dL (1.9 mmol/L) or persistent symptoms of hypocalcaemia despite attempts to increase serum calcium</p></td><td style="vertical-align:top"><p>Reduce or withhold dose of Cinacalcet Tablets.</p></td></tr><tr><td style="vertical-align:top"><p>&le; 7.5 mg/dL (1.9 mmol/L) or persistent symptoms of hypocalcaemia and Vitamin D cannot be increased</p></td><td style="vertical-align:top"><p>Withhold administration of Cinacalcet Tablets until serum calcium levels reach 8.0 mg/dL (2.0 mmol/L) and/or symptoms of hypocalcaemia have resolved.</p><p>Treatment should be reinitiated using the next lowest dose of Cinacalcet Tablets.</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Pediatric population</strong></p><p>Corrected serum calcium should be in the upper range of, or above, the age-specified reference interval prior to administration of first dose of Cinacalcet Tablets, and closely monitored. The normal calcium range differs depending on the methods used by your local laboratory and the age of the child/patient.</p><p>The recommended starting dose for children aged &ge; 3 years to &lt; 18 years is &le; 0.20 mg/kg once daily based on the patient&#39;s dry weight (see table 1).</p><p>The dose can be increased to achieve a desired target iPTH range. The dose should be increased sequentially through available dose levels (see table 1) no more frequently than every 4 weeks. The dose can be increased up to a maximum dose of 2.5 mg/kg/day, not to exceed a total daily dose of 180 mg.</p><p><strong>Table 1. Cinacalcet Tablets daily dose in paediatric patients</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Patient dry weight (kg)</strong></p></td><td><p><strong>Starting dose (mg)</strong></p></td><td><p><strong>Available sequential dose levels (mg)</strong></p></td></tr><tr><td style="vertical-align:top"><p>10 to &lt; 12.5</p></td><td><p>1</p></td><td><p>1, 2.5, 5, 7.5, 10 and 15</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 12.5 to &lt; 25</p></td><td><p>2.5</p></td><td><p>2.5, 5, 7.5, 10, 15, and 30</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 25 to &lt; 36</p></td><td rowspan="2"><p>5</p></td><td><p>5, 10, 15, 30, and 60</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 36 to &lt; 50</p></td><td><p>5, 10, 15, 30, 60, and 90</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 50 to &lt; 75</p></td><td><p>10</p></td><td><p>10, 15, 30, 60, 90, and 120</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 75</p></td><td><p>15</p></td><td><p>15, 30, 60, 90, 120, and 180</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>Dose adjustment based on PTH levels</em></p><p>PTH levels should be assessed at least 12 hours after dosing with Cinacalcet Tablets and iPTH should be measured 1 to 4 weeks after initiation or dose adjustment of Cinacalcet Tablets.</p><p>The dose should be adjusted based on iPTH as shown below:</p><p>&bull; If iPTH is &lt; 150 pg/mL (15.9 pmol/L) and &ge; 100 pg/mL (10.6 pmol/L), decrease the dose of Cinacalcet Tablets to the next lower dose.</p><p>&bull; If iPTH &lt; 100 pg/mL (10.6 pmol/L), stop Cinacalcet Tablets treatment, restart Cinacalcet Tablets at the next lower dose once the iPTH is &gt; 150 pg/mL (15.9 pmol/L). If Cinacalcet Tablets treatment has been stopped for more than 14 days, restart at the recommended starting dose.</p><p><em>Dose adjustment based on serum calcium levels</em></p><p>Serum calcium should be measured within 1 week after initiation or dose adjustment of Cinacalcet Tablets.</p><p>Once the maintenance dose has been established, weekly measurement of serum calcium is recommended. Serum calcium levels in paediatric patients should be maintained within the normal range. If serum calcium levels decrease below the normal range or symptoms of hypocalcaemia occur, appropriate dose adjustment steps should be taken as shown in table 2 below:</p><p><strong>&nbsp;&nbsp; Table 2. Dose adjustment in paediatric patients &ge; 3 to &lt; 18 years of age</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:625px"><tbody><tr><td><p><strong>Corrected Serum calcium value or clinical</strong></p><p><strong>symptoms of hypocalcaemia</strong></p></td><td><p><strong>Dosing recommendations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Corrected serum calcium is at or below agespecified lower limit of normal</p><p><u>or</u></p><p>if symptoms of hypocalcaemia occur, regardless of calcium level.</p></td><td style="vertical-align:top"><p>Stop treatment with Cinacalcet Tablets.*</p><p>Administer calcium supplements, calcium-containing phosphate binders and/or vitamin D sterols, as clinically indicated</p></td></tr><tr><td style="vertical-align:top"><p>Corrected total serum calcium is above agespecified lower limit of normal, <u>and</u></p><p>Symptoms of hypocalcaemia have resolved.</p></td><td style="vertical-align:top"><p>Restart at the next lower dose. If Cinacalcet Tablets treatment has been stopped for more than 14 days, restart at the recommended starting</p><p>dose.</p><p>If patient was receiving the lowest dose (1 mg/day) prior to discontinuation, restart at the same dose (1 mg/day).</p></td></tr></tbody></table><p>&nbsp;</p><p>*If the dose has been stopped, corrected serum calcium should be measured within 5 to 7 days</p><p>The safety and efficacy of Cinacalcet Tablets in children aged less than 3 years for the treatment of secondary hyperparathyroidism have not been established.</p><p><u>Switch from etelcalcetide to Cinacalcet Tablets</u></p><p>The switch from etelcalcetide to Cinacalcet Tablets and the appropriate wash out period has not been studied in patients. In patients who have discontinued etelcalcetide, Cinacalcet Tablets should not be initiated until at least three subsequent haemodialysis sessions have been completed, at which time serum calcium should be measured. Ensure serum calcium levels are within the normal range before Cinacalcet Tablets is initiated.</p><p><em><u>Parathyroid carcinoma and primary hyperparathyroidism</u></em></p><p><em>Adults and elderly (&gt; 65 years)</em></p><p>The recommended starting dose of Cinacalcet Tablets for adults is 30 mg twice per day. The dose of Cinacalcet Tablets should be titrated every 2 to 4 weeks through sequential doses of 30 mg twice daily, 60 mg twice daily, 90 mg twice daily, and 90 mg three or four times daily as necessary to reduce serum calcium concentration to or below the upper limit of normal.</p><p>Serum calcium should be measured within 1 week after initiation or dose adjustment of Cinacalcet Tablets. Once maintenance dose levels have been established, serum calcium should be measured every 2 to 3 months. After titration to the maximum dose of Cinacalcet Tablets, serum calcium should be periodically monitored; if clinically relevant reductions in serum calcium are not maintained, discontinuation of Cinacalcet Tablets therapy should be considered.</p><p><em>Paediatric population</em></p><p>The safety and efficacy of Cinacalcet Tablets in children for the treatment of parathyroid carcinoma and primary hyperparathyroidism have not been established. No data are available.</p><p><em><u>Hepatic impairment</u></em></p><p>No change in starting dose is necessary. Cinacalcet Tablets should be used with caution in patients with moderate to severe hepatic impairment and treatment should be closely monitored during dose titration and continued treatment.</p><p><strong>Method of administration</strong></p><p>For oral use.</p><p>Tablets should be taken whole and should not be chewed, crushed or divided.</p><p>It is recommended that Cinacalcet Tablets be taken with food or shortly after a meal, as studies have shown that bioavailability of cinacalcet is increased when taken with food.</p><p>Cinacalcet Tablets is also available as granules for paediatric use. Children who require doses lower than 30 mg, or who are unable to swallow tablets should receive Cinacalcet Tablets granules.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Hypocalcaemia.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Serum calcium</u></p><p>Life threatening events and fatal outcomes associated with hypocalcaemia may be reported in adult and paediatric patients treated with Cinacalcet Tablets. Manifestations of hypocalcaemia may include paraesthesias, myalgias, cramping, tetany and convulsions. Decreases in serum calcium can also prolong the QT interval, potentially resulting in ventricular arrhythmia secondary to hypocalcaemia. Cases of QT prolongation and ventricular arrhythmia may be reported in patients treated with cinacalcet. Caution is advised in patients with other risk factors for QT prolongation such as patients with known congenital long QT syndrome or patients receiving medicinal products known to cause QT prolongation.</p><p>Since cinacalcet lowers serum calcium, patients should be monitored carefully for the occurrence of hypocalcaemia. Serum calcium should be measured within 1 week after initiation or dose adjustment of Cinacalcet Tablets.</p><p><em>Adults</em></p><p>Cinacalcet Tablets treatment should not be initiated in patients with a serum calcium (corrected for albumin) below the lower limit of the normal range.</p><p>In CKD patients receiving dialysis who were administered Cinacalcet Tablets may lead to lower the serum calcium value less than 7.5 mg/dL (1.9 mmol/L).</p><p><em>Paediatric population</em></p><p>Cinacalcet Tablets should only be initiated for the treatment of secondary HPT in children &ge; 3 years old with ESRD on maintenance dialysis therapy, in whom secondary HPT is not adequately controlled with standard of care therapy, where serum calcium is in the upper range of, or above, the age-specified reference interval. Closely monitor serum calcium levels and patient compliance during treatment with cinacalcet. Do not initiate cinacalcet or increase the dose if non-compliance is suspected.</p><p>Prior to initiating cinacalcet and during treatment, consider the risks and benefits of treatment and the ability of the patient to comply with the recommendations to monitor and manage the risk of hypocalcaemia.</p><p>Inform paediatric patients and/or their caregivers about the symptoms of hypocalcaemia and about the importance of adherence to instructions about serum calcium monitoring, and posology and method of administration.</p><p><em>CKD patients not on dialysis</em></p><p>Cinacalcet is not indicated for CKD patients not on dialysis. The adult CKD patients not on dialysis treated with cinacalcet may have an increased risk for hypocalcaemia (serum calcium levels &lt; 8.4 mg/dL [2.1 mmol/L]) compared with cinacalcet-treated CKD patients on dialysis, which may be due to lower baseline calcium levels and/or the presence of residual kidney function.</p><p><u>Seizures</u></p><p>Cases of seizures may be reported in patients treated with Cinacalcet Tablets. The threshold for seizures may be lowered by significant reductions in serum calcium levels. Therefore, serum calcium levels should be closely monitored in patients receiving Cinacalcet Tablets, particularly in patients with a history of a seizure disorder.</p><p><u>Hypotension and/or worsening heart failure</u></p><p>Cases of hypotension and/or worsening heart failure may be reported in patients with impaired cardiac function, in which a causal relationship to cinacalcet could not be completely excluded and may be mediated by reductions in serum calcium levels.</p><p><u>Co-administration with other medicinal products</u></p><p>Administer Cinacalcet Tablets with caution in patients receiving any other medicinal products known to lower serum calcium. Closely monitor serum calcium.</p><p>Patients receiving Cinacalcet Tablets should not be given etelcalcetide. Concurrent administration may result in severe hypocalcaemia.</p><p><u>General</u></p><p>Adynamic bone disease may develop if PTH levels are chronically suppressed below approximately 1.5 times the upper limit of normal with the iPTH assay. If PTH levels decrease below the recommended target range in patients treated with Cinacalcet Tablets, the dose of Cinacalcet Tablets and/or vitamin D sterols should be reduced or therapy discontinued.</p><p><u>Testosterone levels</u></p><p>Testosterone levels are often below the normal range in patients with end-stage renal disease. The clinical significance of these reductions in serum testosterone is unknown.</p><p><u>Hepatic impairment</u></p><p>Due to the potential for 2 to 4 fold higher plasma levels of cinacalcet in patients with moderate to severe hepatic impairment (Child-Pugh classification), Cinacalcet Tablets should be used with caution in these patients and treatment should be closely monitored.</p><p><u>Lactose</u></p><p>Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Medicinal products known to reduce serum calcium</u></p><p>Concurrent administration of other medicinal products known to reduce serum calcium and Cinacalcet Tablets may result in an increased risk of hypocalcaemia. Patients receiving Cinacalcet Tablets should not be given etelcalcetide.</p><p><u>Effect of other medicinal products on cinacalcet</u></p><p>Dose adjustment of Cinacalcet Tablets may be required if a patient receiving Cinacalcet Tablets initiates or discontinues therapy with a strong inhibitor (e.g. ketoconazole, itraconazole, telithromycin, voriconazole, ritonavir) or inducer (e.g. rifampicin) of this enzyme.</p><p>Dose adjustment may be necessary if a patient starts or stops smoking or when concomitant treatment with strong CYP1A2 inhibitors is initiated or discontinued.</p><p><em>Calcium carbonate</em></p><p>Co-administration of calcium carbonate (single 1,500 mg dose) will not alter the pharmacokinetics of cinacalcet.</p><p><em>Sevelamer</em></p><p>Co-administration of sevelamer (2,400 mg tid) may not affect the pharmacokinetics of cinacalcet.</p><p><em>Pantoprazole</em></p><p>Co-administration of pantoprazole (80 mg od) may not alter the pharmacokinetics of cinacalcet.</p><p>Effect of cinacalcet on other medicinal products</p><p><u>Medicinal products metabolised by the enzyme P450 2D6 (CYP2D6): </u></p><p>Cinacalcet is a strong inhibitor of CYP2D6. Dose adjustments of concomitant medicinal products may be required when Cinacalcet Tablets is administered with individually titrated, narrow therapeutic index substances that are predominantly metabolised by CYP2D6 (e.g. flecainide, propafenone, metoprolol, desipramine, nortriptyline, clomipramine).</p><p><em>Desipramine</em>: Concurrent administration of 90 mg cinacalcet once daily with 50 mg desipramine, a tricyclic antidepressant metabolised primarily by CYP2D6, may increase desipramine exposure in CYP2D6 extensive metabolisers.</p><p><em>Dextromethorphan</em>: Multiple doses of 50 mg cinacalcet may increase the AUC of 30 mg dextromethorphan (metabolised primarily by CYP2D6) by 11-fold in CYP2D6 extensive metabolisers.<em> </em></p><p><em>Warfarin</em>: Multiple oral doses of cinacalcet may not affect the pharmacokinetics or pharmacodynamics (as measured by prothrombin time and clotting factor VII) of warfarin. Cinacalcet is not an inducer of CYP3A4, CYP1A2 or CYP2C9 in humans.</p><p><em>Midazolam</em>: Co-administration of cinacalcet (90 mg) with orally administered midazolam (2 mg), a CYP3A4 and CYP3A5 substrate, may not alter the pharmacokinetics of midazolam. Cinacalcet would not affect the pharmacokinetics of those classes of medicines that are metabolised by CYP3A4 and CYP3A5, such as certain immunosuppressants, including cyclosporine and tacrolimus.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Cinacalcet Tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.</p><p><u>Breast-feeding</u></p><p>It is not known whether cinacalcet is excreted in human milk. Following careful benefit/risk assessment, a decision should be made to discontinue either breast-feeding or treatment with Cinacalcet Tablets.</p><p><u>Fertility</u></p><p>There are no clinical data relating to the effect of cinacalcet on fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cinacalcet Tablets may have major influence on the ability to drive and use machines, since dizziness and seizures may be reported by patients taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile</p><p><em><u>Secondary hyperparathyroidism, parathyroid carcinoma and primary hyperparathyroidism</u></em></p><p>Based on available data from patients receiving cinacalcet in placebo controlled studies and single arm studies the most commonly reported adverse reactions were nausea and vomiting. Nausea and vomiting were mild to moderate in severity and transient in nature in the majority of patients. Discontinuation of therapy as a result of undesirable effects was mainly due to nausea and vomiting.</p><p><em><u>Tabulated list of adverse reactions</u></em></p><p>Adverse reactions, considered at least possibly attributable to cinacalcet treatment in the placebo controlled studies and single-arm studies based on best-evidence assessment of causality are listed below using the following convention: very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000); not known (cannot be estimated from the available data).</p><p>Incidence of adverse reactions from controlled clinical studies and post-marketing experience are:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>MedDRA system organ class</strong></p></td><td><p><strong>Frequency</strong></p></td><td><p><strong>Adverse reaction</strong></p></td></tr><tr><td><p>Immune system disorders</p></td><td><p>Common</p></td><td><p>Hypersensitivity reactions*</p></td></tr><tr><td><p>Metabolism and nutrition disorders</p></td><td><p>Common</p></td><td><p>Anorexia</p><p>Decreased appetite</p></td></tr><tr><td><p>Nervous system disorders</p></td><td><p>Common</p></td><td><p>Seizures</p><p>Dizziness</p><p>Paraesthesia</p><p>Headache</p></td></tr><tr><td><p>Cardiac disorders</p></td><td><p>Not known</p></td><td><p>Worsening heart failure*</p><p>QT prolongation and ventricular</p><p>arrhythmia secondary to</p><p>hypocalcaemia*</p></td></tr><tr><td><p>Vascular disorders</p></td><td><p>Common</p></td><td><p>Hypotension</p></td></tr><tr><td><p>Respiratory, thoracic and mediastinal disorders</p></td><td><p>Common</p></td><td><p>Upper respiratory infection</p><p>Dyspnoea</p><p>Cough</p></td></tr><tr><td rowspan="2"><p>Gastrointestinal disorders</p></td><td><p>Very common</p></td><td><p>Nausea</p><p>Vomiting</p></td></tr><tr><td><p>Common</p></td><td><p>Dyspepsia</p><p>Diarrhoea</p><p>Abdominal pain</p><p>Abdominal pain &ndash; upper</p><p>Constipation</p></td></tr><tr><td><p>Skin and subcutaneous tissue disorders</p></td><td><p>Common</p></td><td><p>Rash</p></td></tr><tr><td><p>Musculoskeletal and connective tissue disorders</p></td><td><p>Common</p></td><td><p>Myalgia</p><p>Muscle spasms</p><p>Back pain</p></td></tr><tr><td><p>General disorders and administration site conditions</p></td><td><p>Common</p></td><td><p>Asthenia</p></td></tr><tr><td><p>Investigations</p></td><td><p>Common</p></td><td><p>Hypocalcaemia</p><p>Hyperkalaemia</p><p>Reduced testosterone levels</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p><em><u>Hypersensitivity reactions</u></em></p><p>Hypersensitivity reactions including angioedema and urticaria have been identified during post-marketing use of cinacalcet. The frequencies of the individual preferred terms including angioedema and urticaria cannot be estimated from available data.</p><p><em><u>Hypotension and/or worsening heart failure</u></em></p><p>There have been reports of idiosyncratic cases of hypotension and/or worsening heart failure in cinacalcet treated patients with impaired cardiac function in post-marketing safety surveillance, the frequencies of which cannot be estimated from available data.</p><p><em><u>QT prolongation and ventricular arrhythmia secondary to hypocalcaemia</u></em></p><p>QT prolongation and ventricular arrhythmia secondary to hypocalcaemia have been identified during post-marketing use of cinacalcet, the frequencies of which cannot be estimated from available data (see section 4.4).</p><p><em><u>Paediatric population</u></em></p><p>The safety of Cinacalcet for the treatment of secondary HPT in paediatric patients with ESRD receiving dialysis was evaluated in two randomised controlled studies and one single-arm study (see section 5.1). Among all paediatric subjects exposed to cinacalcet in clinical studies a total of 19 subjects (24.1%; 64.5 per 100 subject years) had at least one adverse event of hypocalcaemia. A fatal outcome was reported in a paediatric clinical trial patient with severe hypocalcaemia (see section 4.4).</p><p>Cinacalcet should be used in paediatric patients only if the potential benefit justifies the potential risk</p><p><strong>To report any side effect(s):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Saudi Arabia:</em></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Center (NPC)</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call NPC at +966-11-2038222, Ext 2317-2356-2340</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: <u>https://ade.sfda.gov.sa/</u><u> </u></p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Doses titrated up to 300 mg once daily have been administered to adult patients receiving dialysis without adverse outcome. A daily dose of 3.9 mg/kg may be prescribed to a paediatric patient receiving dialysis with subsequent mild stomach ache, nausea and vomiting.</p><p>Overdose of Cinacalcet Tablets may lead to hypocalcaemia. In the event of overdose, patients should be monitored for signs and symptoms of hypocalcaemia, and treatment should be symptomatic and supportive. Since cinacalcet is highly proteinbound, haemodialysis is not an effective treatment for overdose.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Calcium homeostasis, anti-parathyroid agents. ATC code: H05BX01.</p><p><u>Mechanism of action</u></p><p>The calcium sensing receptor on the surface of the chief cell of the parathyroid gland is the principal regulator of PTH secretion. Cinacalcet is a calcimimetic agent which directly lowers PTH levels by increasing the sensitivity of the calcium sensing receptor to extracellular calcium. The reduction in PTH is associated with a concomitant decrease in serum calcium levels.</p><p>Reductions in PTH levels correlate with cinacalcet concentration.</p><p>After steady state is reached, serum calcium concentrations remain constant over the dosing interval.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>After oral administration of Cinacalcet Tablets, maximum plasma cinacalcet concentration will be achieved in approximately 2 to 6 hours. The absolute bioavailability of cinacalcet in fasted subjects has been estimated to be about 20-25%. Administration of Cinacalcet Tablets with food results in an approximate 50&ndash;80% increase in cinacalcet bioavailability. Increases in plasma cinacalcet concentration are similar, regardless of the fat content of the meal.</p><p>At doses above 200 mg, the absorption was saturated probably due to poor solubility.</p><p><u>Distribution</u></p><p>The volume of distribution is high (approximately 1,000 litres), indicating extensive distribution. Cinacalcet is approximately 97% bound to plasma proteins and distributes minimally into red blood cells.</p><p>After absorption, cinacalcet concentrations decline in a biphasic fashion with an initial half-life of approximately 6 hours and a terminal half-life of 30 to 40 hours. Steady state levels of cinacalcet are achieved within 7 days with minimal accumulation. The pharmacokinetics of cinacalcet does not change over time.</p><p><u>Biotransformation</u></p><p>Cinacalcet is metabolised by multiple enzymes, predominantly CYP3A4 and CYP1A2. The major circulating metabolites are inactive.</p><p>Cinacalcet is a strong inhibitor of CYP2D6, but is neither an inhibitor of other CYP enzymes, including CYP1A2, CYP2C8, CYP2C9, CYP2C19, and CYP3A4 nor an inducer of CYP1A2, CYP2C19 and CYP3A4.</p><p><u>Elimination</u></p><p>Approximately 80% of the dose was recovered in the urine and 15% in the faeces.</p><p>Linearity/non-linearity</p><p>The AUC and Cmax of cinacalcet increase approximately linearly over the dose range of 30 to 180 mg once daily.</p><p>Pharmacokinetic/pharmacodynamic relationship(s)</p><p>Soon after dosing, PTH begins to decrease until a nadir at approximately 2 to 6 hours post-dose, corresponding with cinacalcet Cmax. Thereafter, as cinacalcet levels begin to decline, PTH levels increase until 12 hours post-dose, and then PTH suppression remains approximately constant to the end of the once daily dosing interval. PTH levels in Cinacalcet Tablets clinical trials were measured at the end of the dosing interval.</p><p><em>Elderly: </em>There are no clinically relevant differences due to age in the pharmacokinetics of cinacalcet.</p><p><em>Renal insufficiency: </em>The pharmacokinetic profile of cinacalcet in patients with mild, moderate, and severe renal insufficiency, and those on haemodialysis or peritoneal dialysis is comparable to that in healthy volunteers.</p><p><em>Hepatic insufficiency: </em>Mild hepatic impairment did not notably affect the pharmacokinetics of cinacalcet. Compared to subjects with normal liver function, average AUC of cinacalcet was approximately 2-fold higher in subjects with moderate impairment and approximately 4-fold higher in subjects with severe impairment. The mean half-life of cinacalcet is prolonged by 33% and 70% in patients with moderate and severe hepatic impairment, respectively. Protein binding of cinacalcet is not affected by impaired hepatic function. Because doses are titrated for each subject based on safety and efficacy parameters, no additional dose adjustment is necessary for subjects with hepatic impairment.</p><p><em>Gender: </em>Clearance of cinacalcet may be lower in women than in men. Because doses are titrated for each subject, no additional dose adjustment is necessary based on gender.</p><p><em>Paediatric population: </em>After single and multiple once daily oral doses of cinacalcet, plasma cinacalcet concentrations (Cmax and AUC values after normalisation by dose and weight) will be similar to those observed in adult patients.</p><p>There will be no significant impact of age, sex, race, body surface area, and body weight on cinacalcet pharmacokinetics.</p><p><em>Smoking: </em>Clearance of cinacalcet may be higher in smokers than in non-smokers, likely due to induction of CYP1A2-mediated metabolism. If a patient stops or starts smoking, cinacalcet plasma levels may change and dose adjustment may be necessary.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cinacalcet was not teratogenic in rabbits when given at a dose of 0.4 times, on an AUC basis, the maximum human dose for secondary HPT (180 mg daily). The non-teratogenic dose in rats was 4.4 times, on an AUC basis, the maximum dose for secondary HPT. There were no effects on fertility in males or females at exposures up to 4 times a human dose of 180 mg/day (safety margins in the small population of patients administered a maximum clinical dose of 360 mg daily would be approximately half those given above).</p><p>In pregnant rats, there were slight decreases in body weight and food consumption at the highest dose. Decreased foetal weights were seen in rats at doses where dams had severe hypocalcaemia. Cinacalcet has been shown to cross the placental barrier in rabbits.</p><p>Cinacalcet did not show any genotoxic or carcinogenic potential. Safety margins from the toxicology studies are small due to the dose-limiting hypocalcaemia observed in the animal models. Cataracts and lens opacities were observed in the repeat dose rodent toxicology and carcinogenicity studies, but were not observed in dogs or monkeys or in clinical studies where cataract formation was monitored. Cataracts are known to occur in rodents as a result of hypocalcaemia.</p><p>In <em>in vitro </em>studies, IC50 values for the serotonin transporter and KATP channels were found to be 7 and 12-fold greater, respectively, than the EC50 for the calcium-sensing receptor obtained under the same experimental conditions. The clinical relevance is unknown, however, the potential for cinacalcet to act on these secondary targets cannot be fully excluded.</p><p>In toxicity studies in juvenile dogs, tremors secondary to decreased serum calcium, emesis, decreased body weight and body weight gain, decreased red cell mass, slight decreases in bone densitometry parameters, reversible widening of the growth plates of long bones, and histological lymphoid changes (restricted to the thoracic cavity and attributed to chronic emesis) were observed. All of these effects were seen at a systemic exposure, on an AUC basis, approximately equivalent to the exposure in patients at the maximum dose for secondary HPT.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Tablet core: </em>Starch, pregelatinised, Crospovidone, Cellulose, Microcrystalline, Silica colloidal anhydrous, Sodium stearyl fumarate.</p><p><em>Tablet coating:</em></p><p>Opadry II Green 32K510004 contains Lactose monohydrate, Hypromellose, Titanium Dioxide, Triacetin, Iron oxide yellow, FD&amp;C blue #2/indigo caramine aluminium lake.</p><p>Aquarius BP 19156 ICE contains Hypromellose, Polyethylene glycol 6000 and Polyethylene glycol 400. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                        2 years 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30<sup>0</sup>C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Blister Pack</p><p>30 mg &amp; 60 mg &ndash; Blister of 7 Tablets (7&rsquo;s Blister x 4)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Aurobindo Pharma Saudi Arabia Limited,
Jeddah, Saudi Arabia.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                08/2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>